Endocrinological disturbances in chronic obstructive pulmonary disease
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
In this overview, the available literature on endocrinological disturbances in chronic obstructive pulmonary disease (COPD) is reviewed, with stress on growth hormone/insulin-like growth factor I (IGF‐I), thyroid hormone and the anabolic steroids. In COPD, little is known about circulating growth hormone or IGF‐I concentrations. Some authors find a decrease in growth hormone or IGF‐I, others an increase. An increase of growth hormone might reflect a nonspecific response of the body to stress (for instance, hypoxaemia). Until now, only one controlled study on growth hormone supplementation has been published, which however did not reveal any functional benefits. Before growth hormone supplementation can be advised as part of the treatment in COPD, further controlled studies must be performed to investigate its functional efficacy. The prevalence of thyroid dysfunction in COPD and its role in pulmonary cachexia has not been extensively studied. So far, there is no evidence that thyroid function is consistently altered in COPD, except perhaps in a subgroup of patients with severe hypoxaemia. Further research is required to more extensively study the underlying mechanisms and consequences of disturbed thyroid function in this subgroup of COPD patients. A few studies have reported the results of anabolic steroid supplementation in chronic obstructive pulmonary disease. Although some studies have discerned that low circulating levels of testosterone are common in males with chronic obstructive pulmonary disease, little is known about the prevalence, the underlying causes or functional consequences of hypogonadism in these patients. The use of systemic glucocorticosteroids and an influence of the systemic inflammatory response have been suggested as contributing to low testosterone levels. It can be hypothesised that low anabolic hormones will reduce muscle mass and eventually result in a diminished muscle function. Further evidence is required before testosterone replacement can be recommended for males with chronic obstructive pulmonary disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., Bunnell, T. J., Tricker, R., Shirazi, A., & Casaburi, R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607043350101 · Cited by 1,659
Self-citationDyspnea: Mechanisms, Assessment, and Management: A Consensus Statement
(1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.1.ats898 · Cited by 1,052
Peripheral Muscle Weakness in Patients with Chronic Obstructive Pulmonary Disease
BERNARD, S., LeBLANC, P., WHITTOM, F., CARRIER, G., JOBIN, J., BELLEAU, R., & MALTAIS, F. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.158.2.9711023 · Cited by 817
Brodsky, I. G., Balagopal, P., & Nair, K. S. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.10.8855787 · Cited by 444 · cited 1×
“Testosterone has long been recognised for its anabolic properties, which are mediated by the androgen receptor and can be attributed to increases in the fractional synthesis rates of actin and myosin heavy chains [ 22 ].”
BackgroundTestosterone injection stimulates net protein synthesis but not tissue amino acid transport
Ferrando, A. A., Tipton, K. D., Doyle, D., Phillips, S. M., Cortiella, J., & Wolfe, R. R. (1998) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1998.275.5.e864 · Cited by 256
Effect of cigarette smoking on levels of bioavailable testosterone in healthy men
ENGLISH, K. M., PUGH, P. J., PARRY, H., SCUTT, N. E., CHANNER, K. S., & JONES, T. H. (2001) · Clinical Science · doi:10.1042/cs1000661 · Cited by 107 · cited 1×
“This suggests no significant effect of smoking on the biologically active fraction of testosterone [ 28 ].”
Background
Cited by
Maltais, F., Decramer, M., Casaburi, R., Barreiro, E., Burelle, Y., Debigaré, R., Dekhuijzen, P. N. R., Franssen, F., Gayan-Ramirez, G., Gea, J., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201402-0373st · Cited by 1,090
Self-citationSkeletal muscle loss: cachexia, sarcopenia, and inactivity
Evans, W. J. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2010.28608a · Cited by 723
Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease
Troosters, T., Casaburi, R., Gosselink, R., & Decramer, M. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200408-1109so · Cited by 649
Self-citationPossible mechanisms underlying the development of cachexia in COPD
Wagner, P. D. (2008) · European Respiratory Journal · doi:10.1183/09031936.00074807 · Cited by 280
Chronic Obstructive Pulmonary Disease, Asthma, and Risk of Type 2 Diabetes in Women
Rana, J. S., Mittleman, M. A., Sheikh, J., Hu, F. B., Manson, J. E., Colditz, G. A., Speizer, F. E., Barr, R. G., & Camargo, C. A. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2478 · Cited by 269
Metadata
- Authors
- Creutzberg, E. C., & Casaburi, R.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2003-11-02
- Volume
- 22
- Issue
- 46 suppl
- Pages
- 76s-80s
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2110243296
- Cited by
- 114
- References
- 6
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Endocrinological disturbances in chronic obstructive pulmonary disease. https://app.cochat.ai/papers/10.1183/09031936.03.00004610
- The paper
- Creutzberg, E. C., & Casaburi, R. (2003). Endocrinological disturbances in chronic obstructive pulmonary disease. European Respiratory Journal. https://doi.org/10.1183/09031936.03.00004610
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.